Godinov Y

Johnson & Johnson , ,

15 papers

ArticleKetamine

ECHO: Results from a Non-Interventional Cohort Study of Esketamine Nasal Spray in Treatment Resistant Depression

Rosso G, Constant E, De Filippis S +12

Europe PMC2026
ArticleKetamine

Erratum to "Long-term treatment with esketamine nasal spray in patients with treatment resistant depression: Results from the ESCAPE-LTE study" [European Neuropsychopharmacology 107 (2026) 112801].

Reif A, Anıl YA, Bitter I +11

Europe PMC2026
ArticleKetamine

Trajectory of response to esketamine nasal spray for treatment resistant depression: Findings from ESCAPE-TRD.

Young AH, Bartova L, Cardoner N +9

Europe PMC2026
ArticleKetamine

Response to: Commentary on "Long-term treatment with esketamine nasal spray in patients with treatment resistant depression: Results from the ESCAPE-LTE study".

Reif A, Anıl Yağcıoğlu AE, Bitter I +11

Europe PMC2026
ArticleKetamine

Long-term treatment with esketamine nasal spray in patients with treatment resistant depression: Results from the ESCAPE-LTE study.

Reif A, Anıl YA, Bitter I +11

Europe PMC2026
ArticleKetamine

Top-line Results from ESCAPE-LTE: An Open-Label Extension Study to Assess Long-term Safety of Esketamine Nasal Spray in Treatment Resistant Depression

Godinov Y, Fu D, von Holt C +10

Europe PMC2025
ArticleKetamine

Outcomes with esketamine nasal spray in patients with or without earlier partial or full response: post hoc analyses of ESCAPE TRD

Young A, Godinov Y, Rive B +8

Europe PMC2025
ArticleKetamine

Assessment of patient-reported depression severity in subpopulation of ESCAPE-TRD study: esketamine nasal spray versus quetiapine extended release for treatment-resistant depression.

Clemens K, Rive B, Joshi K +7

Europe PMC2025
ArticleKetamine

Efficacy of esketamine nasal spray over quetiapine extended release over the short and long term: sensitivity analyses of ESCAPE-TRD, a randomised phase IIIb clinical trial - ERRATUM.

Young AH, Llorca PM, Fagiolini A +9

Europe PMC2025
ArticleKetamine

Esketamine Nasal Spray vs Quetiapine Extended-Release: Examining Work Productivity Loss and Related Costs in Patients With Treatment-Resistant Depression.

Clemens K, Teeple A, Zhdanava M +6

Europe PMC2025
ArticleKetamine

Esketamine nasal spray versus quetiapine XR in adults with treatment-resistant depression: a secondary analysis of the ESCAPE-TRD randomized clinical trial.

McIntyre RS, Mattingly G, Godinov Y +7

Europe PMC2025
ArticleKetamine

Efficacy of esketamine nasal spray over quetiapine extended release over the short and long term: sensitivity analyses of ESCAPE-TRD, a randomised phase IIIb clinical trial.

Young AH, Llorca PM, Fagiolini A +9

Europe PMC2025
ArticleKetamine

Safety and tolerability of esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression.

McIntyre RS, Bitter I, Buyze J +9

Europe PMC2024
ArticleKetamine

Esketamine Nasal Spray versus Quetiapine for Resistant Depression. Reply.

Reif A, Mulhern-Haughey S, Godinov Y

Europe PMC2024
ArticleKetamine

Esketamine nasal spray shows higher remission and response rates over 32 weeks of treatment compared with quetiapine extended-release in patients with treatment resistant depression: Results from ESCAPE-TRD, a randomised, phase IIIb clinical trial

Reif A, Anıl Yağcıoğlu A, Luts A +10

Europe PMC2023